Against this background, a randomized phase 2a clinical trial of the anti-TSLP monoclonal antibody tezepelumab in the treatment of moderate-to-severe AD patients was conducted but did not reach the targeted level of efficacy (118). The gene discussed is TSLP; the disease is Alzheimer disease.